Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSIP1 | O75475 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | MRGPRX1 | Q96LB2 | 2/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.35 |
| ▸ | BRAF | P15056 | 3/20 | 0.35 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7149258 | 0.89 | ALDH1A1 (0.39) | PDE10ABRAFPTGS1 | |
| SCHEMBL7248382 | 0.86 | NR3C1 (0.41) | PSIP1PDE10AMRGPRX1ADRA2APARP14 | |
| SCHEMBL7100998 | 0.85 | PSIP1 (0.38) | PSIP1PDE10AMRGPRX1ADRA2APARP14 | |
| SCHEMBL7103692 | 0.85 | PSIP1 (0.38) | PSIP1PDE10AMRGPRX1ADRA2APARP14 | |
| SCHEMBL7104778 | 0.83 | PDE10A (0.42) | PSIP1PDE10AMRGPRX1ADRA2APARP14 | |
| SCHEMBL7103402 | 0.83 | MRGPRX1 (0.34) | PDE10AMRGPRX1BRAFPTGS1PTGS2 | |
| Maleic Acid SCHEMBL7508871 | 0.79 | KCNA5 (0.34) | PSIP1PDE10AMRGPRX1ADRA2APARP14 | |
| Fumaric Acid SCHEMBL7508895 | 0.79 | KCNA5 (0.34) | PSIP1PDE10AMRGPRX1ADRA2APARP14 | |
| SCHEMBL7508889 | 0.78 | PDE10A (0.35) | PSIP1PDE10AMRGPRX1ADRA2APARP14 | |
| SCHEMBL7097248 | 0.76 | S100A9 (0.37) | PSIP1MRGPRX1ADRA2AADRA1APTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073850-A1 | 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use | ABBOTT LABORATORIES | 2003-04-17 | — | — | US | disclosed |
| EP-1259491-A1 | 4-IMIDAZOLE DERIVATIVES OF BENZYL AND RESTRICTED BENZYL SULFONAMIDES, SULFAMIDES, UREAS, CARBAMATES AND AMIDES AND THEIR USE AS ALPHA-1A AGONISTS | Abbott Laboratories (US) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001060802-A1 | 4-IMIDAZOLE DERIVATIVES OF BENZYL AND RESTRICTED BENZYL SULFONAMIDES, SULFAMIDES, UREAS, CARBAMATES, AND AMIDES AND THEIR USE AS ALPHA-1A AGONISTS | ABBOTT LABORATORIES (US) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073850-A1 | 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use | ADRA1D, ADRB1, ADRA1A | PSIP1 2844/4885PDE10A 250/4885MRGPRX1 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.